期刊文献+

胃癌中EGFR的表达与临床、病理、预后及多药耐药蛋白P170、TopoⅡ、GST-π表达的关系 被引量:11

EGFR expression and its correlation with P170,TopoⅡ and GST-π in gastric carcinoma and their relationship with clinicopathological data and prognosis
暂未订购
导出
摘要 目的探讨表皮生长因子受体(epidermal growth factor receptor,EGFR)在胃癌中的表达及其与临床病理参数、预后及多药耐药蛋白P-糖蛋白(P-glycoprotein,P170)、DNA拓扑异构酶Ⅱ(topoisomeraseⅡ,TopoⅡ)和谷胱苷肽-S转移酶(glutathione S-transferase-π,GST-π)表达的关系及意义。方法采用免疫组化ABC法检测160例胃癌组织中EGFR、P170、TopoⅡ及GST-π的表达以及EGFR在20例癌旁正常组织中的表达。研究EGFR在胃癌及癌旁正常黏膜中的表达差异,同时分析各因子表达与患者临床病理资料、预后的关系。结果 EGFR在160例胃癌标本中89例阳性,在20例癌旁正常黏膜中2例弱阳性,其在胃癌中的表达明显高于癌旁正常对照组(P<0.05)。EGFR与TopoⅡ的表达呈正相关(P<0.05)。EGFR表达与肿瘤的远处转移相关(P<0.05)。P170表达与肿瘤直径、淋巴结转移、远处转移及TNM分期相关(P<0.05)。GST-π表达与肿瘤远处转移及TNM分期相关(P<0.05)。TopoⅡ表达与病理分级、侵袭深度、远处转移及TNM分期相关(P<0.05)。单因素分析发现患者年龄、肿瘤直径、肿瘤部位、病理分级、侵袭深度、淋巴转移、远处转移、TNM分期、EGFR、TopoⅡ、GST-π均与预后有关(P<0.05)。Cox风险模型多因素分析发现病理分级、TNM分期、EGFR是影响胃癌预后的独立因素(P<0.05)。结论 EGFR在胃癌中高表达,与多药耐药蛋白TopoⅡ表达相关,是预测肿瘤预后的独立因素,可能参与化疗耐药。针对EGFR的分子靶向治疗可能使化疗或辅助化疗耐药,EGFR阳性胃癌患者获得较好的疗效。 Purpose To evaluate the expression of epidermal growth factor receptor (EGFR) in gastric adenocarcinoma and its possi- ble relationship with clinicopathologic parameters, prognosis and correlation with the expression of P-glycoprotein (P170) , topoisomer- ase Ⅱ (Topo Ⅱ ), and glutathione S-transferase-π (GST-π). Methods The expression of EGFR, P170, TopoⅡ and GST-π in 160 cases of gastroadenocarcinoma was detected by immunohistochemistry. The expression of EGFR in 20 cases of relatively normal tissue surrounding cancer were detected by immunohistochemistry. Patients were followed up for more than three years. The relationships be- tween the expression of EGFR, P170, TopoⅡ , GST-π and the clinicopathologic parameters were analyzed. The relationships between these parameters and prognosis of patients were also evaluated. Results EGFR expression in gastric carcinoma was significantly higher than the surrounding tissue. 89 cases of gastric cancer were positive for EGFR. Only 2 surrounding normal tissue showed weak positive for EGFR. There were positive correlation between the expression of P170 and GST-π, Topo Ⅱ and EGFR (P 〈 0.05 ). The expression of EGFR was related to the distal metastasis (P 〈 0. 05 ). The intensity of P170 was related to the diameter of tumor, lymphatic metas- tasis, distant metastasis and TNM stage (P 〈 0. 05). The expression of GST-π was associated to distant metastasis and TNM stage ( P 〈 0. 05). The expression of Topo Ⅱ was related to the grade, distant metastasis, depth of invasion and TNM stage (P 〈 0. 05 ). Univa- riate analysis showed that age, tumor diameter, tumor site, histological type, depth infiltration, lymphatic metastasis, distance metas- tasis, TNM stage and the expression of EGFR, ToPo Ⅱ , GST-π were related to the prognosis of gastric carcinoma (P 〈 0. 05 ). Multi- variate Cox model analysis showed that histological type, TNM stage and EGFR were the independent prognostic factors for the patients (P 〈 0. 05 ). Conclusions The expression of EGFR, Topo Ⅱ , P170 and GST-π is related to some histopathological features. Histo- logical type, TNM stage and EGFR can be regarded as independent prognostic factors in gastric adenocarcinoma. The further study of the prognostic factors will benefit to the diagnosis and treatment of the gastric adenocarcinoma.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2013年第10期1060-1064,1068,共6页 Chinese Journal of Clinical and Experimental Pathology
基金 辽宁省教育厅科学研究一般项目(L2011157)
关键词 胃肿瘤 表皮生长因子受体 P-糖蛋白 DNA拓扑异构酶Ⅱ 谷胱苷肽-S转移酶 预后 stomach neoplasms epidermal growth factor receptor P-glycoprotein topoisomerase Ⅱ glutathione S-transferase-π prognosis
  • 相关文献

参考文献15

  • 1Kulig J, Kolodziejczyk P, Kulig P, et aL Targeted therapy for gastric cancer-current status[ J]. J Oncol Pharm Pract, 2013,19 (1) :75 -81.
  • 2Bronte G, Cicero G, Cusenza S, et al. Monoclonal antibodies in gastrointestinal cancers [ J. Expert Opin Biol Ther, 2013, 13 (6) :889 -900.
  • 3李艳,章明放,郭雪西,李彦敏,蔡文娟,王政禄.胃腺癌中P-gp、ToPoⅡ、GSTπ、MGMT和TS的表达及意义[J].临床与实验病理学杂志,2011,27(11):1193-1196. 被引量:8
  • 4Petitprez A, Larsen A K. h'inotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models [J]. CurrPharmDes, 2013,19(5) :958 -64.
  • 5崔红霞,冯一中.大肠癌中EGFR、nm23、Ki-67的表达及临床意义[J].临床与实验病理学杂志,2011,27(6):647-649. 被引量:14
  • 6Merla A, Goel S. Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review [ J/OL ]. Chemother Res Pract, 2012. http ://www. hindawi, com/j ournals/chevp/2012/387172.
  • 7Kanduc D, Novello G, Mazzanti R. P-170 peptides with low simi- larity to the human proteome: tracing an effective and safe biologi- cal way towards effective and safe cancer chemotherapy[ J ]. J Exp Ther Oncol, 2009,8(2) :151 -5.
  • 8Ruefli A A, Tainton K M, Darcy P K, et al. P-glycoprotein inhib- its caspase-8 activation but not formation of the death inducing sig- nal complex (disc) following fas tigation [ J ]. Cell Death Differ, 2002,9( 11 ) :1266 -72.
  • 9Sau A, Pellizzari Tregno F, Valentino F, et al. Glutathione trans- ferases and development of new principles to overcome drug resist- ance[J]. Arch Biochem Biophys, 2010,500(2) :116 -22.
  • 10Pilati P, Nitti D, Mocellin S. Cancer resistance to type ]I topoi- somerase inhibitors[ J]. Curr Med Chem, 2012,19 (23) :3900 - 6.

二级参考文献14

  • 1Kuansong WANG Jinghe LI Changli ZHEN Jianhua ZHOU Desheng XIAO Jie LIU Ying LIU Haiying JIANG Chen CHEN Jifang WEN.Enhanced Invasive and Metastatic Potential Induced by Transforming Growth Factor-β1 Might be Correlated with Glutathione-S-transferase-π, Cofilin and Heat Shock Protein 27 in SGC-7901 Gastric Cancer Cells[J].Acta Biochimica et Biophysica Sinica,2007,39(7):520-526. 被引量:11
  • 2Kononen J,Bubendorf L,Kallioniemi A,et al.Tissue microarrays for high throughout molecular profiling of tumor specimens[J].Nature Med,1998,4(7):844-7.
  • 3Iseki K,Tatsuata M,Uehara H,et al.Inhibition of angiogenesis as a mechanism for inhibition by 1a-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rat[J].Int J Cancer,1999,81(5):730-3.
  • 4Rocha-Lina C M,Soares H P,Raez L E,et al.EGFR targeting of solid tumors[J].Cancer Control,2007,14(3):295-304.
  • 5Ciardiello F,Tortora G.EGFR antagonists in cancer treatment[J].N Engl J Med,2008,358(11):1660-74.
  • 6Dursun A,Aky(o)rek N,G(o)nel N,et al.Prognostic in plication of nm23-H 1 expression in colorectal carcinomas[J].Pathology,2002,34(5):427-32.
  • 7Suzuki E,Ota T,Tsukuda K,et al.nm23-H1 reduces in vitro cell migration and the liver metastatic potential of colon cancer cells by regulating myosin light chain phosphorylation[J].Int J Cancer,2004,108(2):207-11.
  • 8Leuverink E M,Brennan B A,Crook M L,et al.Prognostic value of mitotic counts and Ki-67 immunoreactivity in adult type granulosa cell tumour of the ovary[J].J Clin Pathol,2008,61(8):914-9.
  • 9Preusser M,Heinzl H,Gelpi E,et al.Ki-67 index in intracranial ependymoma:a promising histopathological candidatebiomarker[J].Histopathology,2008,53(1):39-47.
  • 10Vernillo R,Lorenzi B,Banducci T,et al.Immunohistochemical expression of p53 and Ki-67 in colorectal adenomas and prediction of malignancy and development of new polyps[J].Int J Biol Markers,2008,23(2):89-95.

共引文献19

同被引文献111

  • 1王光锋,孙伟,尹相丛,陈登攀.NM23H1在血清、胃癌组织中表达与胃癌临床TNM分期的关系[J].中国中医药现代远程教育,2009(1):11-12. 被引量:5
  • 2闫冰冰,李力.DNA甲基化与卵巢癌多药耐药及预后的关系[J].中国肿瘤生物治疗杂志,2015,22(3):281-289. 被引量:8
  • 3王晓颖,樊嘉,周俭,邱双健,余耀,刘银坤,汤钊猷.CCR1趋化因子受体在人肝癌组织中表达及其临床意义[J].中华肝胆外科杂志,2006,12(2):101-104. 被引量:20
  • 4陈斌,罗荣城,崔斐,钱新宇.胃癌HER-2/neu基因表达与预后的相关性[J].南方医科大学学报,2006,26(3):344-347. 被引量:45
  • 5Petitprez A,Larsen AK.Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models[J].Curr Pharm Des,2013,19(5):958-964.
  • 6Merla A,Goel S.Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review[J].Chemother Res Pract,2012:387172.
  • 7Kanduc D,Novello G,Mazzanti R.P-170 peptides with low similarity to the humart proteome: tracing an effective attd safe biological way towards effective and safe cancer chemotherapy[J].J Exp Ther Oncol,2009,8(2): 151-155.
  • 8Pilati P,Nitti D,Mocellin S.Cancer resistance to type II topoisomerase inhibitors[J].Curr Med Chem,2012,19(23):3900-3906.
  • 9Mayo C,Bertran-Alamillo J,Molina-Vila M,h,,et al.Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications[J].Pharmac ogenomics,2012,13(7):789-802.
  • 10GE F, WANG C, WANG W, et al. S100 P predicts prognosis and drug resistance in gastric cancer[J]. Int J Biol Markers, 2013, 28:e387-e392.

引证文献11

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部